US Corporate Distress Financial Stress SEC Filings — July 02, 2026

02-07-2026

Bluerock Private Real Estate Fund entered into an Administrative Services Agreement with its adviser, Bluerock Fund Advisor, LLC, effective July 1, 2026, to provide expanded administrative services as the fund rotates from institutional funds into direct real estate investments. The ASA fee is 0.20% of average managed assets, but the adviser voluntarily waived approximately 53% of the fee on assets still in institutional funds, resulting in significant net savings for shareholders. The fund also disclosed it has closed approximately $250 million in direct real estate investments and has an additional $450 million under contract or in its pipeline.

• · The ASA fee is calculated and paid monthly based on average daily managed assets (net assets plus borrowings plus preferred stock liquidation preference).
• · The ASA can be terminated by a majority of independent trustees, a majority of outstanding voting securities, or by the adviser upon 60 days' written notice without penalty.
• · The ASA covers services including NYSE listing compliance, secondary market support, proxy and annual meeting process, and Exchange Act reporting.
• · The adviser's liability is limited to cases of willful misfeasance, bad faith, gross negligence, or reckless disregard of obligations.

02-07-2026

Beeline Holdings, Inc. acquired the remaining 52.4% of MagicBlocks, Inc. through a Securities Exchange Agreement effective June 30, 2026, making MagicBlocks a wholly-owned subsidiary. The transaction involved nominal cash consideration for selling shareholders, issuance of 211,679 shares to Third-Party SAFE Holders (including CEO Nicholas R. Liuzza, Jr., who received 31,111 shares at $2.25 per share), and cancellation of all outstanding MagicBlocks stock options. Separately, from May 27 to June 26, 2026, the company raised $1,575,098.23 in gross proceeds by selling 1,370,131 shares under an existing ELOC Agreement.

• · The transaction was negotiated and approved by a Special Committee of the Board comprised solely of disinterested directors due to CEO involvement.
• · CEO received 31,111 shares at $2.25 per share, which was materially above market.
• · All outstanding MagicBlocks stock options were cancelled as part of the agreement.
• · The ELOC share sales were made under an exemption from registration under Section 4(a)(2) of the Securities Act and Rule 506(b).

02-07-2026

American Rebel Holdings Inc. issued a $152,950 promissory note to 1800 Diagonal Lending LLC on June 23, 2026, receiving net proceeds of $133,000 after an original issue discount of $19,950. The note carries a 15% interest rate (18.75% one-time charge) and requires 15 monthly payments totaling $181,628, with a maturity date of September 30, 2027. However, the company faces a high effective cost of capital (implied interest of ~36.6% on net proceeds) and the note includes severe default penalties (150%-200% of outstanding) and cross-default provisions, indicating significant financial strain.

• · The note is secured by a Securities Purchase Agreement and includes cross-default provisions with all other debt of the borrower to the holder.
• · The company has a 5-day grace period for each monthly payment; a missed payment constitutes an Event of Default.
• · Upon an Event of Default, the holder can demand 150% of the outstanding principal plus accrued interest and default interest; this increases to 200% if a conversion default occurs.
• · The borrower cannot prepay except during the first 180 days, and then only at 95% of the outstanding amount (a 5% discount).
• · The note includes covenants restricting sale of significant assets without holder consent and requires the borrower to remain current with its transfer agent obligations.
• · The holder has conversion rights into common stock upon an Event of Default (other than conversion failure) and if the borrower fails to pay the Default Amount within 5 business days.

02-07-2026

EquipmentShare.com Inc closed a private offering of $1,350 million aggregate principal amount of 7.125% Senior Secured Second Lien Notes due 2034, issued at par. The notes mature on July 1, 2034, with interest payable semi-annually. The company has the option to redeem up to 10% of the notes at 103% of par within any twelve-month period before July 1, 2029, and up to 40% with equity offering proceeds at 107.125% of par. The notes are secured on a second-priority basis and rank pari passu with existing second lien notes, but are junior to the asset-based revolving credit facility.

• · The notes are not guaranteed by any subsidiary as of the issue date but will be guaranteed by future domestic subsidiaries that guarantee first-priority lien obligations.
• · The notes rank pari passu with existing 9.000% Senior Secured Second Lien Notes due 2028, 8.625% Senior Secured Second Lien Notes due 2032, and 8.000% Senior Secured Second Lien Notes due 2033.
• · The indenture includes customary high yield covenants limiting additional debt, dividends, liens, affiliate transactions, mergers, asset sales, and subsidiary dividend restrictions.
• · Interest on the notes is payable on January 1 and July 1, beginning January 1, 2027.

02-07-2026

Neurogene Inc. raised approximately $134.8 million in net proceeds through an underwritten public offering of 3,500,000 shares of common stock at $30.00 per share and pre-funded warrants for 666,666 shares at $29.999999 per warrant, with the underwriters fully exercising a 30-day option to purchase an additional 624,999 shares. The company expects the funds, combined with existing cash, to support operations into the first quarter of 2029. The offering closed on July 2, 2026, and the securities were offered under an effective shelf registration statement.

• · The underwriters fully exercised their 30-day option to purchase an additional 624,999 shares on July 1, 2026.
• · Pre-funded warrants are exercisable at any time after issuance, with a beneficial ownership cap of 4.99% or 9.99% (can be increased to up to 19.99% with 61 days' notice).
• · The offering was made under shelf registration statement File No. 333-286057, effective April 4, 2025.
• · The final prospectus supplement was filed with the SEC on July 1, 2026.

02-07-2026

CareView Communications Inc. entered into the Fifteenth Amendment to its Credit Agreement with lender PDL Investment Holdings, LLC, extending the maturity date from June 30, 2026 to September 30, 2026. This is the latest in a long series of short-term extensions, indicating ongoing reliance on lender forbearance and no resolution of the company's debt obligations.

• · The Fifteenth Amendment to the Credit Agreement was entered into on June 30, 2026.
• · The amendment extends the Maturity Date to September 30, 2026.
• · The original Credit Agreement was dated June 26, 2015.
• · The company has entered into at least 14 prior amendments to the Credit Agreement and 30 amendments to the Modification Agreement.
• · The lender is PDL Investment Holdings, LLC, as assignee of PDL BioPharma, Inc.

02-07-2026

Idaho Copper Corporation announced the pricing of an $18 million underwritten public offering of common stock and warrants at $4.85 per share, with a 45-day over-allotment option for up to 556,800 additional shares. The offering is expected to close on July 6, 2026, and the shares will begin trading on the NYSE American on July 2, 2026. Proceeds will fund an updated Preliminary Economic Assessment, initial Prefeasibility Study work, and general corporate purposes.

• · The CuMo project is one of the largest undeveloped copper deposits in the western hemisphere and likely the largest undeveloped molybdenum deposit in the world.
• · The project contains significant amounts of silver, rhenium, and tungsten.
• · The registration statement on Form S-1 (File No. 333-290746) became effective on July 1, 2026.
• · ThinkEquity is acting as sole book-running manager for the offering.
• · The company's ticker symbols on NYSE American are COPR and COPR WS.

02-07-2026

Vaxart, Inc. entered into a cooperation agreement with the Stockholder Group to resolve its proxy contest ahead of the 2026 Annual Meeting. The agreement includes appointing a mutually agreed independent director, forming a Stockholder Engagement Committee and a Clinical and Regulatory Affairs Committee, refreshing board committee chairs, and adopting director stock ownership and resignation policies. The Stockholder Group withdrew its director nominations. The settlement aims to unify focus on upcoming value-inflection milestones and enhance corporate governance, but no specific financial or operational targets were disclosed.

• · Vaxart is a clinical-stage biotechnology company developing oral recombinant vaccines using an adenovirus and TLR3 agonist platform.
• · The cooperation agreement includes formation of a Stockholder Engagement Committee and a Clinical and Regulatory Affairs Committee.
• · The agreement provides for board committee refreshment, including new chairs for the Nominating and Governance and Compensation Committees.
• · The cooperation agreement includes customary standstill, voting, and engagement provisions for the Stockholder Group.
• · The search for the additional independent director will be conducted within 90 days of the conclusion of the 2026 Annual Meeting.

02-07-2026

Elicio Therapeutics announced a $15 million registered direct offering of 4,380,313 shares, led by two new institutional investors with participation from an existing large shareholder. The net proceeds will primarily fund the planned Phase 1 clinical development of ELI-002 7P in metastatic PDAC and general corporate purposes. However, the company's Phase 2 AMPLIFY-7P trial showed immature overall survival data, and the Phase 1 study is subject to funding, highlighting ongoing clinical and financial risks.

• · The offering is being made under a shelf registration statement on Form S-3 (File No. 333-293861) declared effective on March 16, 2026.
• · Closing of the offering is expected on or about July 6, 2026.
• · ELI-002 7P targets seven of the most common KRAS mutations present in 25% of all solid tumors.
• · Phase 2 AMPLIFY-7P trial data for overall survival remained immature at the time of analysis.
• · Elicio plans to expand ELI-002 7P to other indications including mKRAS-positive lung cancer.
• · Pipeline includes ELI-007 (BRAF-driven cancers) and ELI-008 (p53 hotspot mutations).

02-07-2026

Arcturus Therapeutics announced a strategic collaboration with Thermo Fisher Scientific to support Phase 3 development and potential commercialization of ARCT-032, an investigational mRNA therapy for cystic fibrosis. Thermo Fisher will provide integrated manufacturing, clinical research, and commercial readiness services, with exclusive commercial manufacturing rights subject to regulatory approval. The collaboration leverages Thermo Fisher's Accelerator™ Drug Development solutions to help accelerate the program, though Phase 2 results are still pending and regulatory approval is uncertain.

• · Arcturus developed KOSTAIVE®, the first self-amplifying mRNA COVID vaccine approved globally.
• · Arcturus has an ongoing global collaboration with CSL Seqirus and U.S. BARDA for pandemic flu.
• · Arcturus has a joint venture in Japan, ARCALIS, focused on mRNA vaccine and therapeutic manufacturing.
• · Arcturus' pipeline includes RNA therapeutic candidates for cystic fibrosis and ornithine transcarbamylase (OTC) deficiency, plus partnered mRNA vaccine programs for COVID-19 and influenza.
• · Arcturus' technologies cover multiple nucleic acid medicines including mRNA, siRNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics.
• · Arcturus holds over 500 patents and patent applications globally.

02-07-2026

Kartoon Studios adopted a limited duration stockholder rights plan (poison pill) to protect shareholder interests, not in response to any specific takeover bid. The plan involves a dividend distribution of one right per outstanding common share, with a record date of July 13, 2026. The company continues to position itself for sustained growth through its global children's entertainment portfolio, including Stan Lee Universe and Mainframe Studios.

• · Kartoon Channel! is consistently rated as the #1 kids’ streaming app on the Apple App Store.
• · The company has a global distribution footprint in over 60 territories.
• · Kartoon Studios holds a controlling interest in Stan Lee Universe.
• · Mainframe Studios is one of North America’s largest animation producers.

02-07-2026

RenovoRx, Inc. (RNXT) received a second 180-day extension from Nasdaq, until December 28, 2026, to regain compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market. The company failed to meet the original compliance deadline of June 30, 2026, and must now maintain a closing bid price of at least $1.00 for 10 consecutive business days during the Second Compliance Period.

• · Original deficiency notice received December 31, 2025, with first compliance deadline of June 30, 2026.
• · If not compliant by December 28, 2026, Nasdaq will issue a delisting notice; the company may appeal to a Hearings Panel.
• · Company is an emerging growth company and has not elected to use the extended transition period for new accounting standards.

02-07-2026

Dot Ai, Inc. (Nasdaq: DAIC) announced the retirement in full of its outstanding secured convertible promissory notes held by White Lion Capital, LLC, totaling approximately $867,000, releasing associated security interests and eliminating that debt. Additionally, a new investor has advanced $500,000 in new secured convertible financing as a first step toward a potential significant transaction. While these actions strengthen the balance sheet and simplify the capital structure, the company noted that the related letter of intent is non-binding and there is no assurance that a definitive transaction will be completed.

• · The retirement of the White Lion notes releases all security interests that secured those notes.
• · The new $500,000 convertible note is provided by a potential new investor previously contemplated in a non-binding LOI.
• · The LOI relates to a sale of a portion of the Company’s operating business, but is non-binding and subject to numerous conditions.
• · There is no assurance that definitive agreements will be executed or that the proposed transaction will be completed.
• · The company serves industries including aviation, construction, delivery, military, mining, retail, sea ports, medical logistics, warehousing, and manufacturing.

02-07-2026

HUMBL, INC. (HMBL) reported revenue of $30 million for the quarter ended March 31, 2026, representing a 20% increase year-over-year. However, the company reported a net loss of $5 million, compared to a net loss of $4 million in the same period last year, and operating expenses increased by 15% to $28 million. The filing highlights strong growth in transaction volume, but also notes a decline in user growth rate and increasing operational costs.

• · Transaction volume grew by 40% YoY to $2.5 billion.
• · Cash and cash equivalents decreased to $8 million from $12 million in the prior year quarter.
• · Customer acquisition costs increased by 18% YoY.
• · HUMBL, INC. launched a new AI-driven recommendation engine during the quarter.

02-07-2026

Centrus Energy signed a $900 million contract with the U.S. Department of Energy to deploy commercial-scale HALEU production capacity, with total contract value including options reaching $1.07 billion. The company completed production of an additional 900 kilograms of HALEU UF6 ahead of schedule, transitioning from a demonstration contract to commercialization. However, the first new capacity is not expected online until 2029, and the company faces risks including government funding uncertainties and geopolitical conflicts.

• · The demonstration contract was originally won in 2019 and modified/extended in 2022.
• · The new contract is fixed-price and includes options for up to $170 million in HALEU purchases.
• · Centrus expects the initial build-out to achieve nth-of-a-kind centrifuge manufacturing costs.
• · The expansion is underpinned by public and private funding including national security missions, third-party investments, prepayment, direct foreign investment, and commercial contracts.
• · Centrus has provided more than 1,850 reactor years of fuel since 1998, equivalent to more than 7 billion tons of coal.

02-07-2026

Motorcar Parts of America extended CEO Selwyn Joffe's employment agreement to July 1, 2029, and approved two salary increases: from $828,256 to $902,799 per annum effective June 26, 2026, and further to $984,050 per annum effective April 1, 2027. No negative or flat metrics are reported in this filing.

• · The Amendment was approved by the Human Resources and Compensation Committee and the Board of Directors.
• · All other terms of the Employment Agreement remain unchanged.
• · The term was extended by two years, from July 1, 2027 to July 1, 2029.

02-07-2026

Sky Quarry Inc., together with co-obligors Foreland Refining Corp. and 2020 Resources LLC, entered into a Conversion and Exchange Agreement with Libertas Funding LLC to convert approximately $3.985M in outstanding merchant cash advance obligations into a single 8% promissory note, extinguishing all prior MCA agreements and remedies. The restructuring reduces near-term cash flow pressure from daily/weekly ACH debits and provides a more traditional debt structure, but the company remains highly leveraged. CEO Marcus Laun is providing a personal guarantee on the new note.

• · The MCA Agreements originated from fundings on October 23, 2023, January 12, 2024, January 18, 2024, and February 23, 2024.
• · The new note carries an 8% interest rate and is not registered under the Securities Act of 1933.
• · Libertas is an accredited investor and is acquiring the note for investment purposes only.
• · The conversion is irrevocable—MCA Agreements cannot be reinstated even in the event of a default under the note.
• · Upon closing, all prior MCA remedies including 'Bad Acts' provisions, ACH debit authorizations, and acceleration rights are nullified.
• · Closing conditions include execution of the note, personal guarantee, and no existing event of default under the note.
• · The agreement is governed by Delaware law.

02-07-2026

Tenon Medical, Inc. announced a $4.2 million public offering of 11,052,631 shares (or pre-funded warrants) at a combined price of $0.38 per share with common warrants. Proceeds will be used for debt repayment, commercial expansion, and R&D. The offering is led by WallachBeth Capital, with the securities already registered with the SEC.

• · The offering includes up to 13,263,159 common warrants exercisable at $0.38 per share.
• · Pre-funded warrants are exercisable at $0.001 per share and may be exercised at any time until fully exercised.
• · The company expects to use net proceeds for partial repayment of outstanding convertible notes, commercial expansion, training clinicians, hiring direct sales reps, expanding distribution network, clinical research for reimbursement, R&D for future launches, inventory/instrumentation increases, marketing, and working capital.
• · Tenon acquired substantially all assets of SiVantage, Inc. and SIMPL Medical, LLC in August 2025, including the SImmetry+® SI Joint Fusion System.
• · The offering was priced on June 30, 2026.

02-07-2026

Veru Inc. entered into a Sales Agreement with Oppenheimer & Co. Inc. and Canaccord Genuity LLC to sell up to $21.8 million of its common stock in at-the-market offerings. The company will pay a 3.0% commission on gross proceeds and is not obligated to sell any shares. No prior-period comparisons are available in this filing.

• · The Sales Agreement was entered into on July 2, 2026.
• · The offering is registered under the Company's Registration Statement on Form S-3 (File No. 333-294911), effective April 15, 2026.
• · Sales may be made by any method permitted by law deemed an 'at the market offering' under Rule 415(a)(4).
• · The Company will reimburse the Sales Agents for certain specified expenses.
• · The Company has provided customary indemnification and contribution rights to the Sales Agents.

02-07-2026

Abacus Global Management, Inc. entered into a First Amendment to its Credit Agreement on June 29, 2026, securing $75 million in incremental term loans, bringing total commitments to $225 million. The amendment maintains existing interest rate terms (SOFR + 5.25% with a potential stepdown to 5.00%) and extends maturity to December 2030. Separately, director Sean McNealy resigned effective June 30, 2026, in connection with his planned retirement, with no disagreement with the company.

• · The Incremental Term Loans may be prepaid at any time in amounts of $1.0 million or greater, subject to a 1.00% premium if prepaid within 12 months of funding.
• · Undrawn amounts under the DDTL facility bear a commitment fee until drawn or cancelled.
• · Sean McNealy will remain as an advisor during a transition period and will resign from all subsidiary director/officer roles by December 31, 2026.
• · The Amendment was filed as Exhibit 10.1 to the 8-K.

02-07-2026

Analog Devices, Inc. entered into a new Credit Agreement dated July 2, 2026, with Bank of America as Administrative Agent and a syndicate of lenders including Citibank, JPMorgan Chase, Morgan Stanley, Barclays, and BNP Paribas. The agreement provides for committed loan facilities with pricing tied to the company's debt rating, ranging from 0.480% to 0.925% for Term SOFR/Alternative Currency Loans and facility fees from 0.020% to 0.075%. The agreement includes customary representations, covenants, and events of default, and allows for designated borrowers among the company's subsidiaries.

• · The Credit Agreement is dated July 2, 2026, and includes the Company and certain subsidiaries as Designated Borrowers.
• · The agreement provides for committed loans and includes a Term-Out Option (Section 2.19).
• · Interest rates are based on Term SOFR, Base Rate, or Alternative Currency rates (SONIA for Sterling, EURIBOR for Euro).
• · The agreement includes a financial covenant (Section 7.07) and negative covenants regarding Liens, Fundamental Changes, and Use of Proceeds.
• · The agreement contains standard events of default and remedies (Article VIII).
• · The agreement includes provisions for extension of maturity date (Section 2.14) and replacement of lenders (Section 10.13).
• · The agreement is governed by the laws of the State of New York (Section 10.14).

02-07-2026

FTAI Infrastructure Inc. (FIP) subsidiary Jefferson 2020 Bond Borrower LLC entered into a $230 million bridge loan credit agreement with Jefferies Finance LLC as administrative agent and sole lead arranger. The loan carries escalating interest margins starting at 5.50% (Term Benchmark) and requires a $20 million debt service reserve. Proceeds will refinance existing debt, fund the reserve, and pay transaction fees.

• · The loan is structured as a bridge facility with escalating interest margins that increase every 90 days, starting at 5.50% (Term Benchmark) and reaching 7.50% after 360 days.
• · The agreement includes mandatory prepayment provisions based on Excess Cash Flow (ECF Sweep) with a 75% sweep when Leverage Ratio >= 6.00:1.00 and 50% when < 6.00:1.00.
• · The borrower is required to maintain a $20 million debt service reserve account.
• · The loan is secured by collateral as defined in the Security Documents (Article X).
• · The agreement contains typical representations, warranties, covenants, and events of default for a secured credit facility.

02-07-2026

Cheniere Corpus Christi Holdings, LLC entered into a $1.5B revolving credit agreement dated June 26, 2026, with lenders including The Bank of Nova Scotia (agent) and Société Générale (security trustee), to provide working capital for its Corpus Christi LNG project. The facility amends and restates a prior working capital facility. No financial performance data was provided in this filing.

• · The agreement is governed by Delaware law and includes covenants on limitations on indebtedness, liens, and restricted payments.
• · The facility is classified as Working Capital Debt under the Finance Documents and amends/restates the existing working capital facility agreement.
• · The agreement includes provisions for letters of credit (with specific forms for Transcontinental Gas Pipeline Company and Gas Supply letters), swing line loans, and incremental commitments.
• · The facility is secured under the Second Amended and Restated Common Security and Account Agreement dated June 15, 2022 (as amended).

02-07-2026

Backblaze, Inc. filed an 8-K on July 2, 2026, reporting Item 1.01 (Entry into a Material Definitive Agreement) and Item 9.01 (Financial Statements and Exhibits). The filing indicates a material agreement was entered into, but no specific financial terms, counterparty, or strategic details are disclosed in the summary. The filing is timely and mandatory, but the lack of quantitative data limits assessment of financial impact or market reaction.

• · Filing date: July 2, 2026
• · AccNo: 0001628280-26-046865
• · Size: 173 KB
• · Items reported: 1.01 and 9.01
• · No specific agreement details, counterparty, or financial terms disclosed in the summary

02-07-2026

Castellum, Inc. filed an 8-K on July 2, 2026, reporting entry into a material definitive agreement (Item 1.01) and departure/appointment of officers with compensatory arrangements (Item 5.02). No financial details or transaction values were disclosed. The filing is multi-item but lacks quantitative data, making assessment of materiality and market impact uncertain.

• · Filed on July 2, 2026, with AccNo 0001877939-26-000057.
• · Size of filing: 181 KB.
• · No financial statements or exhibits were provided in the summary.

02-07-2026

W. P. Carey Inc. completed a public offering of $350 million in 5.200% Senior Notes due 2036 on July 2, 2026. The net proceeds will be used to repay $350 million of its 4.250% Senior Notes due October 2026 and for general corporate purposes, including funding potential investments and repaying other indebtedness. The offering was made under an existing shelf registration statement and a final prospectus supplement dated June 29, 2026.

• · The Senior Notes mature on September 15, 2036.
• · Interest on the Senior Notes is payable semi-annually on March 15 and September 15, commencing March 15, 2027.
• · The Senior Notes are unsecured and unsubordinated obligations ranking equally with existing and future unsecured and unsubordinated debt.
• · The company may redeem the notes at any time at the make-whole redemption price; after June 15, 2036, redemption price is 100% of principal plus accrued interest.
• · The indenture includes covenants requiring a specified ratio of unencumbered assets to unsecured debt and limiting incurrence of secured and unsecured indebtedness, subject to significant exceptions.
• · The offering was made under an automatic shelf registration statement (File No. 333-286885) filed on May 1, 2025.

02-07-2026

Haverty Furniture Companies Inc. and its subsidiary Havertys Credit Services Inc. entered into a Sixth Amendment to their Amended and Restated Credit Agreement with Truist Bank, effective June 29, 2026. The amendment increases the revolving loan commitments from $80 million to $100 million, providing additional liquidity. The filing confirms no defaults are continuing and all representations and warranties remain true.

• · The amendment was entered into on June 29, 2026, and filed on July 2, 2026.
• · The credit agreement was originally dated September 1, 2011.
• · No Default or Event of Default is continuing as of the effective date.
• · The amendment is governed by the internal laws of the State of Georgia.
• · The amendment reaffirms the security interests and liens granted to the Administrative Agent under the credit agreement.

02-07-2026

Ares Core Infrastructure Fund (the Equityholder and Servicer) and its SPV subsidiary ACI Liquid Aggregator SPV, LLC amended their existing revolving credit and security agreement with BNP Paribas (Administrative Agent and Lender) and U.S. Bank Trust Company (Collateral Agent) on June 26, 2026. The amendment updates terms via redlined changes to the agreement, schedules, and exhibits; the borrower and servicer represent no default is continuing and all representations remain true. No specific financial metrics or performance data were disclosed in the filing, limiting the ability to assess the fund's financial trajectory.

• · The underlying Revolving Credit and Security Agreement was originally dated September 23, 2025.
• · No monetary amounts or changes to facility size, interest rates, or fees were disclosed in the amendment.
• · The amendment was governed by New York law and required a legal opinion from Latham & Watkins LLP.
• · The borrower represented that no Default or Event of Default is continuing as of the amendment date.

02-07-2026

NextDecade Corp's indirect subsidiary, Rio Grande LNG, LLC, completed a $3.5 billion senior secured notes offering on July 2, 2026, comprising four tranches with maturities from 2031 to 2041 and interest rates ranging from 5.250% to 6.150%. The net proceeds will be used to repay a portion of outstanding borrowings under existing credit agreements and pay related fees and expenses. The notes are senior secured obligations ranking pari passu with existing and future secured indebtedness under the Common Terms Agreement.

• · The Notes were issued under an Indenture dated July 2, 2026, with Wilmington Trust as Trustee.
• · Interest on 2031, 2036, and 2041 Notes is payable semi-annually on December 30 and June 30, beginning December 30, 2026.
• · Interest on 2034 Notes is payable semi-annually on January 30 and July 30, beginning January 30, 2027.
• · The Indenture includes customary covenants limiting RGLNG's ability to incur additional debt, make investments, pay dividends, sell assets, incur liens, and merge.
• · Upon a change of control event, RGLNG must offer to repurchase the Notes at 101% of principal; for other events (asset sales, loss, liquidated damages), repurchase at par.
• · The Notes were offered only to qualified institutional buyers under Rule 144A and to non-U.S. investors under Regulation S; not registered under the Securities Act.
• · The Indenture is a senior secured debt instrument under the Common Terms Agreement dated July 12, 2023, as amended.

02-07-2026

Elroy Air, Inc. entered into a Securities Purchase Agreement on June 25, 2026, to issue convertible promissory notes and warrants to institutional investors in a private placement under Section 4(a)(2) of the Securities Act. The financing is part of a broader transaction that includes a Business Combination Agreement with SPAC Columbus Circle Capital Corp II (CMII). The filing does not disclose specific dollar amounts, conversion terms, or warrant details, limiting immediate quantitative assessment.

• · The Securities Purchase Agreement is dated June 25, 2026, and involves institutional investors as purchasers.
• · The securities are being offered under Section 4(a)(2) of the Securities Act, exempt from public registration.
• · The Company is concurrently entering into a separate securities purchase agreement (Other SPA) with other purchasers on substantially the same terms.
• · The Business Combination Agreement with SPAC Columbus Circle Capital Corp II is anticipated but not yet executed as of the filing date.
• · Purchasers must be qualified institutional buyers or institutional accredited investors under Rule 144A or Rule 501(a).
• · The securities are subject to transfer restrictions and will bear a restrictive legend.
• · The Purchaser releases the Placement Agent from any losses or claims related to the offering.
• · No specific dollar amounts, conversion prices, interest rates, or warrant exercise prices are disclosed in this exhibit.

02-07-2026

Pyxis Oncology announced a private placement financing with gross proceeds of approximately $50 million upfront, plus up to $64 million from warrant exercises, led by BVF Partners L.P. The financing is expected to extend the company's cash runway into Q2 2027 and support the advancement of its lead ADC candidate MICVO through key clinical milestones. However, the company has delayed its next clinical data update for the Phase 1 monotherapy study to Fall 2026 (previously expected earlier), and the Phase 1/2 combination data is now expected in Q4 2026, indicating a shift in timelines.

• · The private placement is expected to close on or about July 2, 2026.
• · Wells Fargo Securities acted as sole placement agent.
• · The company has elected to incorporate additional patient follow-up and planned analyses into its next clinical update, delaying the monotherapy data release to Fall 2026.
• · The Phase 1/2 combination data with pembrolizumab is expected in Q4 2026.
• · MICVO received Fast Track Designation from the FDA for R/M HNSCC after progression on platinum-based chemotherapy and anti-PD-(L)1 therapy.
• · The warrants have a cashless exercise feature.

02-07-2026

BridgeBio Pharma raised $1 billion in convertible preferred equity led by Sixth Street ($800M) and HealthCare Royalty ($133.9M) to accelerate product launches. The financing strengthens the balance sheet as Attruby grows into a multi-billion-dollar drug and three additional potential blockbuster launches are planned within 12 months. However, the preferred stock carries a 7.00% dividend and a conversion price at a more than 100% premium to the 30-day VWAP, which may dilute common shareholders if converted.

• · The preferred stock has no scheduled maturity and no redemption at the holder's option.
• · BridgeBio may redeem the preferred stock for cash or convert it into common stock under certain circumstances.
• · Sixth Street has over $130 billion in assets under management and committed capital.
• · HealthCare Royalty has committed $7+ billion in over 110 biopharmaceutical products.
• · The financing is intended to support launches of Attruby, BBP-418, encaleret, and infigratinib.

02-07-2026

KKR Private Equity Conglomerate LLC filed a Seventh Amended and Restated Limited Liability Company Agreement (LLCA) on July 2, 2026, restating the Sixth A&R Agreement in its entirety. The filing updates governance provisions, share repurchase plans, and distribution reinvestment plans, but contains no new financial performance data or operational metrics. The original capital contribution of $1,000 for 40 Class G Shares on December 6, 2022, remains unchanged; no growth, decline, or period-over-period comparisons are available in this filing.

• · Filing amends and restates the Sixth A&R Agreement dated December 4, 2024.
• · Initial capital contribution on December 6, 2022 was $1,000 for 40 Class G Shares.
• · Schedules include Share Repurchase Plan, Distribution Reinvestment Plan, and Repurchase Arrangement for Class E Shares.
• · Manager KKR DAV Manager LLC serves as attorney-in-fact for all Members.
• · No financial performance data, revenue, profit, or operational metrics are disclosed in this filing.

02-07-2026

Alpha Modus Holdings, Inc. entered into a Securities Purchase Agreement with Streeterville Capital, LLC on June 29, 2026, for the issuance of common shares through pre-paid purchases. The agreement includes provisions for registration, listing, and an exchange cap under Nasdaq rules, with shareholder approval required to exceed the cap. No specific monetary amounts or share quantities are disclosed in the filing.

• · The agreement relies on an exemption from securities registration under the Securities Act of 1933.
• · Company must file a PRE14C with the SEC within 30 days of closing and a DEF14C to notify stockholders of the approval to exceed the Exchange Cap.
• · Company is obligated to cure any Material Outside Event within 10 Trading Days.
• · Company must publicly disclose all material non-public information delivered to Investor after filing the Current Report.

02-07-2026

Alcoa Corporation has entered into a binding Umbrella Implementation Deed dated June 30, 2026, to acquire South32 Limited's Australian, Brazilian, and South African assets (sale shares) through multiple buying entities. The transaction involves a mix of cash and Alcoa shares as consideration, with conditions precedent including FIRB approval, regulatory consents, and shareholder approvals. The deal includes break fee and reverse break fee provisions, a locked-box leakage mechanism, and post-completion restraints on competition and employee solicitation.

• · The deed is governed by the laws of Western Australia.
• · Consideration includes a Cash Purchase Price, Contingent Consideration (Schedule 11), and Consideration Shares (Alcoa common stock).
• · A South African Assets Buyer must be incorporated or acquired within 21 days of the deed date.
• · The transaction is subject to FIRB Act approval, regulatory consents, and an independent expert report for South32 shareholders.
• · Break Fee and Reverse Break Fee provisions are included (clause 22).
• · Post-completion restraints include a non-compete covenant (clause 18) and non-solicitation of employees (clause 19).
• · Alcoa must file a Form S-4 with the SEC and list Alcoa CDIs on the ASX.
• · The deed includes a locked-box mechanism with leakage reimbursement (clause 10).

02-07-2026

HeartBeam, Inc. received a Nasdaq deficiency notice on June 30, 2026, for failing to maintain a minimum bid price of $1.00 per share for 30 consecutive business days. The company has a 180-day compliance period until December 28, 2026, to regain compliance, and may qualify for a second 180-day period if it meets other listing standards. There is no immediate impact on listing, but failure to regain compliance could lead to delisting.

• · The company's common stock trades under the symbol BEAT on the Nasdaq Capital Market.
• · The company's warrants trade under the symbol BEATW on the Nasdaq Capital Market.
• · The company is an emerging growth company and has not elected to use the extended transition period for complying with new or revised financial accounting standards.
• · If the company fails to regain compliance by December 28, 2026, it may be eligible for a second 180-day compliance period if it meets the market value of publicly held shares requirement and all other initial listing standards except the minimum bid price.

02-07-2026

Functional Brands Inc. amended CEO Eric Gripentrog's employment agreement on June 30, 2026, replacing a $500,000 RSU award with an option to purchase 3,500,000 shares at $0.0055 per share, fully vested immediately. The option has a grant-date fair value of approximately $14,685 and a total exercise price of $19,250. No negative or flat metrics are present.

• · The option is designated as an incentive stock option under Section 422 of the Internal Revenue Code.
• · Exercise price of $0.0055 per share equals the closing price on June 29, 2026.
• · Option expires on June 29, 2036, subject to earlier termination.
• · Upon cessation of service (other than death/disability), vested shares may be exercised within 3 months.

02-07-2026

Creative Medical Technology Holdings, Inc. (CELZ) raised approximately $4.5 million in gross proceeds through an inducement offer to exercise existing warrants at $1.60 per share, while the CEO received a $100,000 bonus approved on July 1, 2026. The transaction involved issuing new warrants for 5,580,680 shares and included financial advisory fees of 8% of gross proceeds plus $50,000 in expense reimbursements to Roth Capital Partners.

• · The Inducement Warrants have a five-year exercise term starting only after stockholder approval is obtained, as required by Nasdaq rules.
• · The resale registration statement for the Inducement Warrants must be filed within 30 days of closing.
• · The Existing Warrants were originally issued on October 29, 2025.
• · The inducement reduced the exercise price from $2.86 to $1.60 per share.
• · The shares underlying the Existing Warrants were already registered under an effective S-3 (File No. 333-291713).
• · No period-over-period comparisons are available in this filing.

02-07-2026

At a special meeting on July 1, 2026, Origin Materials stockholders voted to approve the complete liquidation and dissolution of the company under a Plan of Dissolution, with 2,043,101 votes for, 66,752 against, and 13,326 abstentions. The meeting also granted discretionary authority to the Board to adjourn for further proxy solicitation if needed, with 1,975,944 votes for, 116,556 against, and 30,679 abstentions. The votes reflect strong shareholder support for dissolution, though 3.3% of votes were against the dissolution proposal and 5.9% against the adjournment proposal.

• · The special meeting was held on July 1, 2026 and the record date for voting was May 20, 2026.
• · No broker non-votes were reported for either proposal, indicating all shares present were voted.
• · A total of 2,123,179 shares (38.58% of outstanding) constituted a quorum.
• · The adjournment proposal received 1,975,944 votes for (93.0%), 116,556 against (5.5%), and 30,679 abstentions (1.4%).
• · The filing was signed on July 1, 2026 by Secretary and General Counsel Joshua Lee.

02-07-2026

TD SYNNEX Corporation entered into a European receivables securitization program on June 26, 2026, with a EUR 650 million senior variable funding notes facility. The program involves multiple subsidiaries and banks, including BNP Paribas, Banco Santander, and Crédit Agricole, and is structured as a revolving securitization with a scheduled amortization date of June 25, 2028, extendable to June 2031. The company also provided a guaranty for certain obligations under the transaction documents.

• · The program involves seller entities in Belgium, France, Germany, and Spain.
• · Interest on senior and junior notes accrues over weekly interest periods and is payable in arrears on weekly payment dates.
• · The MDCTA includes ratings-based performance thresholds tied to TD SYNNEX Corporation's credit ratings (Level 2 and Level 3 Required Ratings).
• · Early amortization events include payment defaults, reporting failures, insolvency events, material adverse events, cross-defaults, and portfolio trigger breaches.
• · The last day of borrowing is June 25, 2028, with an option to extend to June 2031.
• · The transaction documents provide for limited recourse and non-petition in favor of the Issuer.

02-07-2026

On June 29, 2026, BNB Plus Corp. amended its Registration Rights Agreement with purchasers holding 50.1% or more of Registrable Securities, extending the filing deadline to 30 calendar days after a Final Closing that must occur on or before July 17, 2026. The amendment, effective June 23, 2026, involved parties including Comstock Multichain Fund and KGPLA Holdings LLC. No financial figures were disclosed, and no negative or flat performance metrics are evident from this filing.

• · The amendment extends the 'Filing Date' to 30 calendar days after the Final Closing date of all purchasers of Registrable Securities.
• · Final Closing must occur on or before July 17, 2026.
• · The amendment is the first modification to the Registration Rights Agreement originally dated May 26, 2026.
• · Exhibit 10.1 is attached and incorporated by reference.

02-07-2026

Cheniere Energy, Inc. increased its revolving credit facility commitments by $500M to $1.75B and extended the maturity date by one year to August 1, 2031, with over 50% of lenders consenting. The transaction involved multiple existing and new lenders, including Société Générale as administrative agent, and was effective June 26, 2026.

• · The maturity extension was from August 1, 2030 to August 1, 2031.
• · The commitment increase was allocated among multiple Additional Commitment Lenders as per Schedule I (not provided).
• · New Lenders joined the credit agreement as per Schedule IV (not provided).
• · The agreement was governed by New York law.
• · No novation occurred; existing obligations remained in full force.

02-07-2026

Boxlight Corp received a Nasdaq delisting notice on July 1, 2026 for failing to meet the $2.5 million stockholders' equity requirement. The company plans to request a hearing to appeal the suspension and is exploring financing alternatives, including a potential stock issuance approved by shareholders on June 2, 2026. However, there is no assurance the Panel will grant continued listing or that Boxlight can regain compliance within any extension period.

• · The delisting notice was received on July 1, 2026, and the 8-K was filed on July 2, 2026.
• · Shareholders approved potential issuance of 20% or more of outstanding Class A Common Stock at the annual meeting on June 2, 2026.
• · The company is exploring financing alternatives but has not yet entered into a definitive agreement.
• · There is no assurance the Panel will grant continued listing or that Boxlight can demonstrate compliance within any extension period.

02-07-2026

On July 1, 2026, AI Financial Corporation (AIFC) received a Nasdaq notification that its common stock has failed to maintain the minimum $1.00 bid price for 30 consecutive business days, making it non-compliant with continued listing rules. The company has a 180-day cure period (until December 28, 2026) to regain compliance by achieving a closing bid price of at least $1.00 for 10 consecutive business days. AIFC intends to explore options including a potential reverse stock split to remedy the deficiency, but faces delisting risk if compliance is not achieved within the cure period.

• · The deficiency period ended on June 30, 2026, which was the 30th consecutive business day of non-compliance.
• · If compliance is not regained by December 28, 2026, Nasdaq may grant an additional 180 days, subject to meeting other listing standards (excluding the bid price rule) and a written notice of intent to cure.
• · If the company fails both cure periods, Nasdaq will notify AIFC of a delisting determination, after which the company may appeal to a Hearings Panel.

02-07-2026

KKR Infrastructure Conglomerate LLC filed an 8-K on July 2, 2026, announcing the adoption of its Sixth Amended and Restated Limited Liability Company Agreement, which governs the company's governance, capital structure, and member rights. The filing also includes updates to share repurchase, distribution reinvestment, and repurchase arrangements. No financial results or performance metrics were disclosed in this filing.

• · The company was originally formed on September 23, 2022, and this is the sixth amendment and restatement of its LLC agreement.
• · The agreement includes provisions for share repurchase, distribution reinvestment, and repurchase arrangements as detailed in Schedules A, B, and C.
• · The Manager is KKR DAV Manager LLC, a Delaware limited liability company.
• · The filing includes updates to governance, including board composition, officer roles, and conflict of interest standards.

02-07-2026

Kite Realty Group, L.P. priced a $300 million offering of 3.25% exchangeable senior notes due 2032, with an option for an additional $45 million. Net proceeds of approximately $291.8 million (or $335.7 million if the option is exercised) will be used to enter into capped call transactions, repurchase $30 million of common shares, and repay $300 million of 4.00% senior unsecured notes due 2026. The exchange price of $35.40 per share represents a 22.5% premium over the $28.90 closing price on June 29, 2026.

• · Interest on the notes is payable semi-annually on April 15 and October 15, beginning April 15, 2027.
• · Notes mature on April 15, 2032, unless earlier exchanged, repurchased, or redeemed.
• · Before January 15, 2032, exchange is only permitted upon certain circumstances and during certain periods; after that date, holders may exchange at any time.
• · The exchange rate is subject to anti-dilution adjustments but not for accrued interest.
• · The Operating Partnership may redeem the notes on or after July 20, 2029, if the stock price is at least 130% of the exchange price for 20 trading days in a 30-day period.
• · The Operating Partnership may also redeem notes to preserve REIT status or if less than 10% of the initial principal remains outstanding.
• · Capped call transactions cover the number of common shares underlying the notes and have a cap price of approximately $41.91 per share.
• · Option Counterparties may engage in hedging activities that could affect the market price of the common shares or notes.
• · The notes and underlying common shares are not registered under the Securities Act and are offered only to qualified institutional buyers.
• · As of March 31, 2026, the company owned interests in 169 properties totaling approximately 27.3 million square feet.

02-07-2026

Nuvve Holding Corp., through its subsidiary Nuvve Denmark ApS, entered into a Sale and Purchase Agreement on June 22, 2026 to acquire all equity interests of BESS Sibiu SRL, a Romanian company developing a 42 MW battery energy storage project in Sibiu, Romania. The total consideration includes a monthly development fee of €10,000 (~$11,420), an initial purchase price of ~€420,000 (~$480,000) subject to adjustments, a COD payment of ~€1,260,000 (~$1,440,000) contingent on receiving a generation license, and repayment of seller loans of RON 946,000 (~$206,000). The agreement is subject to customary closing conditions and Romanian regulatory approvals, with an automatic termination date of October 22, 2026 if conditions are not met.

• · The agreement automatically terminates if closing conditions are not fulfilled or waived by October 22, 2026.
• · The COD payment is contingent on receipt of a generation license from the Romanian Energy Regulatory Authority.
• · The initial purchase price is subject to adjustments including a financial guarantee amount, seller loan amount, and net working capital adjustments.
• · The agreement is governed by Romanian law and requires approval from Romania's commission on foreign direct investment.

02-07-2026

Mangoceuticals, Inc. (MGRX) entered into a Subscription Agreement with an accredited investor on June 29, 2026, issuing 850,000 shares of restricted common stock at $0.32 per share for total proceeds of $272,000. The offering was conducted as a private placement under Section 4(a)(2) and Rule 506 of Regulation D, with piggyback registration rights for one year. No underwriters or commissions were involved, and the shares are subject to transfer restrictions.

• · The offering was exempt from registration under Section 4(a)(2) and Rule 506 of Regulation D.
• · The investor is an accredited investor and had access to similar information as would be in a registration statement.
• · No general solicitation was used, and no underwriters or agents were involved.
• · The shares carry transfer restrictions and a restrictive legend.
• · Piggyback registration rights are granted for one year from the subscription date.

02-07-2026

Snail, Inc. filed an 8-K announcing a 1-for-5 reverse stock split of its Common Stock (both Class A and Class B), effective July 2, 2026 at 11:59 PM ET. No fractional shares will be issued; holders otherwise entitled to a fractional share will receive a cash payment based on the average closing price of Class A Common Stock on Nasdaq for the ten days preceding the effective time. The filing also includes items related to delisting/failure to satisfy a listing rule, indicating the company may be addressing Nasdaq minimum bid price requirements.

• · The reverse stock split applies to both Class A Common Stock and Class B Common Stock.
• · Fractional shares will not be issued; cash payment will be based on the average closing sales price of Class A Common Stock on Nasdaq for the ten days preceding the effective time.
• · The amendment was approved by the Board of Directors and requisite stockholders.
• · The certificate of amendment was signed on July 1, 2026, and becomes effective at 11:59 PM ET on July 2, 2026.